Skip to content

Insider · CIK 0001632454

Joseph S McCracken

director

Files at LUMOS PHARMA, INC., SVRA (Savara Inc). First filing Nov 20, 2024, latest Nov 20, 2024.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$59k bought, $0 sold

Where the trades landed

Last year at the company this insider has traded most, with each buy and sell on the bar it happened.

SVRA: Savara Inc

SVRAOct 9, 2026 · close 4.92

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

This insider’s open-market buys and sells, scored.

ScoreCompanyValueHoldingsPrice contextFiled
33Weak
SVRAbuy 2
Savara Inc
$59k
20,000 shares
+10%-

Transactions

Every row this insider has filed, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Dec 12, 2024SVRA
Savara Inc
AGrant or award
Common Stock
+40,000$0.00$0250,837Dec 16, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Common Stock
-15,721--0Dec 13, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-3,345--0Dec 13, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-3,328--0Dec 13, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-5,684--0Dec 13, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-3,431--0Dec 13, 2024
Dec 12, 2024-
LUMOS PHARMA, INC.
DDisposition to issuer
Stock Option (Right to Buy)derivative
-2,910--0Dec 13, 2024
Nov 19, 2024SVRA
Savara Inc
POpen-market purchase
Common Stock
+20,000$2.95$59k210,837Nov 20, 2024

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Joseph S McCracken: insider trades and track record | InsiderTell